Hepatitis C ‘Buyers’ Club’ Highlights Issues Surrounding Access To Drugs

New York Times: The Tasmanian Hep C Buyers’ Club
Sophie Cousins, health journalist

“…[After traveling to India to obtain the less-expensive generic version of the hepatitis C drug sofosbuvir, Australian Greg Jefferys] helped other former hepatitis C sufferers set up informal buyers’ clubs in their own countries. … Narcyz Ghinea, a researcher in health ethics at the School of Public Health at the University of Sydney, says the online facilitation of access to unapproved drugs raises a lot of questions. … Ghinea believes the popularity of personal importation could become a powerful negotiating tool to reduce drug prices. But he worries that the purchase of cheaper generic drugs overseas could undercut the market and reduce pharmaceutical companies’ incentive to develop drugs … It could also compromise discount plans provided to low-income countries. Another risk is that the drugs could be fakes. … But those who run the informal buyers’ clubs insist they work only with licensed pharmaceutical suppliers. … Personal importation is not the way the world will get access to a hepatitis C cure. It’s a short-term stopgap for a few, one that highlights problems with drug costs, access, and the role regulatory bodies play…” (7/25).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KFF | twitter.com/kff

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.